KATO Labssp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-03-18
Share capital
50,000.00 PLN
Registered address
Marszałkowska 138/82, 00-004 Warszawa, Poland
Electronic delivery address
AE:PL-79425-98532-UTSRG-27

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 434 days for 2019).

  • 2025not filed
  • 202416/07/2025
  • 202316/07/2025
  • 202222/09/2023
  • 202122/09/2023
  • 202023/12/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 7.23mMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 2.17mMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 4.53mMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 8.12mMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

KATO Labs holds 14 active trademarks registered with the Polish Patent Office. 13 marks have expired or were not registered. The first mark was filed in 1998.

MarkNumberClassesStatusProtected until
Grypolek TABLETKI POWLEKANE 24 Paracetamolum + Guaifenesinum + Pseudoephedrini hydrochloridum + Dextromethorphani hydrobromidumZ.5777105Protected Dec 2, 2034
KATO LABSZ.5428133, 5, 35, 39Protected May 6, 2032
Icy Rub Gel(word)Z.5282583, 5Protected Apr 28, 2031
BÓLOXEN(word)Z.5282565Protected Apr 28, 2031
DERMACTAN(word)Z.4563703, 5, 30Protected May 13, 2036
MarkProtected until
Grypolek TABLETKI POWLEKANE 24 Paracetamolum + Guaifenesinum + Pseudoephedrini hydrochloridum + Dextromethorphani hydrobromidumDec 2, 2034
KATO LABSMay 6, 2032
Icy Rub Gel(word)Apr 28, 2031
BÓLOXEN(word)Apr 28, 2031
DERMACTAN(word)May 13, 2036

Authorized Representatives

Agata Kasia Wołejko – Attorney-in-fact (sole)
Janusz Ambroży Wołejko – Attorney-in-fact (sole)
Phillip Marek Wołejko – President of the Management Board

Manner of representation

Member of the management board independently, commercial proxy independently, individually.

Ownership

OwnerSharesShare valueStake
Julia Teresa Lemmensage 42
23$3,106.4323%
Agata Kasia Wołejkoage 47
23$3,106.4323%
Phillip Marek Wołejkoage 47
45$6,077.8045%
Others
9$1,215.569%

Phillip Marek Wołejko and Agata Kasia Wołejko hold a combined 68% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2001-05-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$110

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Anpharm Przedsiębiorstwo FarmaceutyczneS.A.
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.
VercoS.A.
MedicofarmaS.A.
VitamaS.A.
Munar PharmaS.A.
Sanford Biotechsp. z o.o.
Cefeasp. z o.o.
Auxilius PharmaS.A.
Stg25Branch (foreign co.)

FAQ

Last updated: 2026-04-04